Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightHavva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: [email protected] Available at www.actaoncologicaturcica.com
📌 3 Maddede Bu Makale
Özet
Address for Correspondence: Uzm. Dr. Havva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: [email protected] Available at www.actaoncologicaturcica.com
Abstract
chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1). However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment. These are abdominal pain, bleeding, blockage, leakage, movement, malfunction, and/or access problems (2). Peritoneovaginal fistula is a rare complication of IP treatment, “leaky vaginal cuff” was the reason for discontinuation of treatment 2 of the 71 patients in a study (3). Although the significant improvement on survival, IP chemotherapy should be given carefully